A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice
- 17 March 2013
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 56 (6) , 1417-1424
Abstract
We designed a chemically modified, enzyme-resistant peptide with triple-acting properties based on human glucagon with amino acid substitutions aligned to strategic positions in the sequence of glucose-dependent insulinotropic polypeptide (GIP).Keywords
This publication has 32 references indexed in Scilit:
- Minireview: Glucagon in the Pathogenesis of Hypoglycemia and Hyperglycemia in DiabetesEndocrinology, 2012
- Glucagon-like Peptide–1 Analogues for Type 2 Diabetes MellitusDrugs, 2011
- DPP‐IV‐resistant, long‐acting oxyntomodulin derivativesJournal of Peptide Science, 2011
- The Alpha-Cell as Target for Type 2 Diabetes TherapyThe Review of Diabetic Studies, 2011
- Pancreatic β-cell overexpression of the glucagon receptor gene results in enhanced β-cell function and massAmerican Journal of Physiology-Endocrinology and Metabolism, 2009
- Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in MiceDiabetes, 2009
- Biologic actions and therapeutic potential of the proglucagon-derived peptidesNature Clinical Practice Endocrinology & Metabolism, 2005
- Degradation, Insulin Secretion, and Antihyperglycemic Actions of Two Palmitate-DerivitizedN-Terminal Pyroglutamyl Analogues of Glucose-Dependent Insulinotropic PolypeptideJournal of Medicinal Chemistry, 2005
- Beta- and Alpha-Cell Dysfunction in Type 2 DiabetesHormone and Metabolic Research, 2004
- Solid phase peptide synthesis utilizing 9‐fluorenylmethoxycarbonyl amino acidsInternational Journal of Peptide and Protein Research, 1990